Baidu
map

Eur Heart J:肥厚性心肌病女性患者的生存率更差

2017-09-09 xiangting MedSci原创

由于HCM女性的生存率更差,性别是HCM管理中的重要决定因素。

肥厚性心肌病(HCM)的性别差异尚不清楚。这项研究试图描述一个大型HCM转诊中心人群中的性别差异。

3673名HCM成人患者于1975年1月至2012年9月期间进行了评估,其中女性1661人(45.2%)。通过时序检验评估Kaplan-Meier生存率曲线。Cox比例风险回归分析评估了性别与生存率的关系。女性的年龄较大(59±16岁vs 52±15岁,P<0.0001),有更多症状[纽约心脏协会(NYHA)III-IV级45.0%vs.35.3%,P<0.0001],更多的阻塞性生理(77.4%vs. 71.8%,P= 0.0001),更多的二尖瓣反流(中度或更高56.1%vs.43.9%,P<0.0001),E/e比更高(n= 1649,20.6 vs.15.6 ,P<0.0001),较高的估算肺动脉收缩压(n= 1783,40.8±15.4vs.比34.8±10.8 mmHg,P<0.0001),更差的心肺运动功能(n= 1267;VO2预测值%62.8±20%vs.65.8±19.2%,P= 0.007),更多的酒精隔膜消融(4.9%vs. 3.0%,P= 0.004),但切除率相似(28%vs.30%,P= 0.24)。中位随访为10.9年(IQR 7.4-16.2)。Kaplan-Meier分析显示女性与男性相比,其生存率较低(P 血管并发症调整后,女性性别与死亡率(HR 1.13 [1.03-1.22],P = 0.01)独立相关。

女性HCM患者比男性的年龄更大、症状更多、心肺运动耐力更差、血液动力学也不同。因为HCM女性的生存率更差,性别是HCM管理中的重要决定因素。女性可能需要更积极的诊断和治疗方式。

原始出处:
Jeffrey B. Geske, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 7 September 2017. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033509, encodeId=ebb0203350934, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 21 23:25:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256596, encodeId=f6b312565966f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356506, encodeId=03bd13565061e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562693, encodeId=4125156269329, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622280, encodeId=efa71622280b9, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033509, encodeId=ebb0203350934, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 21 23:25:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256596, encodeId=f6b312565966f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356506, encodeId=03bd13565061e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562693, encodeId=4125156269329, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622280, encodeId=efa71622280b9, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033509, encodeId=ebb0203350934, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 21 23:25:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256596, encodeId=f6b312565966f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356506, encodeId=03bd13565061e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562693, encodeId=4125156269329, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622280, encodeId=efa71622280b9, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=)]
    2017-09-11 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033509, encodeId=ebb0203350934, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 21 23:25:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256596, encodeId=f6b312565966f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356506, encodeId=03bd13565061e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562693, encodeId=4125156269329, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622280, encodeId=efa71622280b9, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=)]
    2017-09-11 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033509, encodeId=ebb0203350934, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Feb 21 23:25:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256596, encodeId=f6b312565966f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356506, encodeId=03bd13565061e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562693, encodeId=4125156269329, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622280, encodeId=efa71622280b9, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Sep 11 02:25:00 CST 2017, time=2017-09-11, status=1, ipAttribution=)]

相关资讯

JACC:成年肥厚性心肌病与低心血管死亡率及当代医疗管理的联系

背景:肥厚性心肌病(HCM)与不良并发症显著相关,包括突然死亡或心脏衰竭死亡和一般不良预后,年死亡率高达6%。    意义:该研究确定管理策略的最新进展,包括植入型心律转复除颤器(ICD),心脏移植,或其他治疗措施是否可以显著改善成人HCM患者的临床过程和生存。    方法:研究人员评估了1000个连续的成年HCM年龄在30至59岁(平均

JAHA:梗阻性肥厚性心肌病患者门诊服用双异丙吡胺的安全性分析!

由此可见,在门诊患者使用双异丙吡胺治疗是安全的,其随后的心脏猝死风险较低。由于其延长QT间期的效应,对尖端扭转性心律失常高风险的患者进行防范是有必要的。

Circ Heart Fail:心肺运动试验可以作为肥厚性心肌病的预后因素

  英国伦敦大学心血管科学研究所的Coats CJ等人研究了心肺运动试验对于肥厚性心肌病患者预后的作用,研究成果发表在9月份 Circulation Heart failure期刊上。背景:  运动试验经常被用于肥厚型心肌病(HCM)患者,用来评估血压反应(一项心源性猝死的危险因素)。对运动气体交换变量的预后作用尚未可知。方法和结果:    1998年至20

Science:证实药物MYK-461可阻止和逆转肥厚性心肌病

MyoKardia公司作为一家开创精准医疗治疗遗传性心血管疾病的生物制药公司2月4日宣布在Science期刊上发表了一篇论文,论文标题为“A Small-Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice”。这篇论文证实作为该公司的候选先导药物(lead drug

JAMA:肥厚性心肌病患者是否能够进行中强度运动?

为肥厚性心肌病患者制定运动建议具有一定的挑战性,因为运动可以引发室性心律失常,并且,尚未在该人群中获得临床受益。近期,一项发表在权威杂志JAMA上的研究旨在确定中等强度运动训练是否能够提高成人肥厚性心肌病患者的运动能力。此项研究在美国2个学术医疗中心(密歇根大学健康系统和斯坦福大学医学中心)进行,自2010年4月至2015年10月期间进行了共136例肥厚性心肌病患者的随机临床试验。最后一次随访日期

Circulation:肥厚性心肌病遗传外显率调查

丹麦一项旨在调查肥厚性心肌病(HCM)在儿童和成人中的外显率的为期12年的临床筛查和预防性基因检测随访研究表明,在表型阴性的在危儿童亲属中,12年后发生HCM的外显率为6%。20多岁发生的表型转换现象需要进一步进行成人期筛查。42%的儿童亲属是非携带者。该研究11月28日在线发表于《循环》(Circulation)杂志。 HCM在儿童和成人期的外显率仅被少量提及,研究者分析了HCM的外显

Baidu
map
Baidu
map
Baidu
map